Ewing Sarcoma - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 210 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 1 and 2 molecules, respectively.Ewing Sarcoma.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ewing Sarcoma Overview 8
Therapeutics Development 9
Pipeline Products for Ewing Sarcoma - Overview 9
Pipeline Products for Ewing Sarcoma - Comparative Analysis 10
Ewing Sarcoma - Therapeutics under Development by Companies 11
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes 13
Ewing Sarcoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Ewing Sarcoma - Products under Development by Companies 16
Ewing Sarcoma - Products under Investigation by Universities/Institutes 18
Ewing Sarcoma - Companies Involved in Therapeutics Development 19
Astellas Pharma Inc. 19
Cebiotex, S.L. 20
Celgene Corporation 21
EntreChem, S.L. 22
Exelixis, Inc. 23
Gradalis Inc. 24
Kolltan Pharmaceuticals, Inc. 25
Merck & Co., Inc. 26
Merrimack Pharmaceuticals, Inc. 27
NanoSmart Pharmaceuticals, Inc. 28
Nanovalent Pharmaceuticals Inc. 29
NantKwest, Inc. 30
Novartis AG 31
Oncomatryx Biopharma, S.L. 32
Oncternal Therapeutics, Inc. 33
Pfizer Inc. 34
Pharma Mar, S.A. 35
Recombio S.L 36
Shionogi & Co., Ltd. 37
Tesaro, Inc. 38
Ewing Sarcoma - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
axitinib - Drug Profile 50
cabozantinib s-malate - Drug Profile 56
CEB-01 - Drug Profile 74
Cellular Immunotherapy for Oncology - Drug Profile 75
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 77
celyvir - Drug Profile 78
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile 79
EC-8042 - Drug Profile 80
EC-8105 - Drug Profile 81
everolimus - Drug Profile 82
gemogenovatucel-T - Drug Profile 94
haNK Program - Drug Profile 98
irinotecan hydrochloride - Drug Profile 99
KITSG-3227 - Drug Profile 110
KTN-0182A - Drug Profile 111
linsitinib - Drug Profile 112
lurbinectedin - Drug Profile 114
Monoclonal Antibody Conjugate for Ewing Sarcoma - Drug Profile 121
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 122
niraparib - Drug Profile 123
NV-101 - Drug Profile 129
OMTX-503 - Drug Profile 130
OMTX-703 - Drug Profile 131
ONC-206 - Drug Profile 132
paclitaxel albumin bound - Drug Profile 133
pazopanib hydrochloride - Drug Profile 141
pembrolizumab - Drug Profile 148
racotumomab - Drug Profile 185
RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile 187
roneparstat - Drug Profile 188
S-588410 - Drug Profile 189
Small Molecules for Ewing Sarcoma - Drug Profile 191
SP-2509 - Drug Profile 192
SP-2528 - Drug Profile 193
SP-2577 - Drug Profile 194
TK-216 - Drug Profile 195
Vimo-101 - Drug Profile 196
Ewing Sarcoma - Dormant Projects 197
Ewing Sarcoma - Discontinued Products 199
Ewing Sarcoma - Product Development Milestones 200
Featured News & Press Releases 200
Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 207
Disclaimer 208

List of Tables

Number of Products under Development for Ewing Sarcoma, H2 2016 11
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H2 2016 21
Ewing Sarcoma - Pipeline by Cebiotex, S.L., H2 2016 22
Ewing Sarcoma - Pipeline by Celgene Corporation, H2 2016 23
Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2016 24
Ewing Sarcoma - Pipeline by Exelixis, Inc., H2 2016 25
Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2016 26
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 27
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H2 2016 28
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 29
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2016 30
Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016 31
Ewing Sarcoma - Pipeline by NantKwest, Inc., H2 2016 32
Ewing Sarcoma - Pipeline by Novartis AG, H2 2016 33
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H2 2016 34
Ewing Sarcoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016 35
Ewing Sarcoma - Pipeline by Pfizer Inc., H2 2016 36
Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H2 2016 37
Ewing Sarcoma - Pipeline by Recombio S.L, H2 2016 38
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016 39
Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 49
Number of Products by Stage and Molecule Type, H2 2016 51
Ewing Sarcoma - Dormant Projects, H2 2016 199
Ewing Sarcoma - Dormant Projects (Contd..1), H2 2016 200
Ewing Sarcoma - Discontinued Products, H2 2016 201